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COMMENT&RESPONSE
Study on the Risk of Cutaneous Squamous Cell
CarcinomaAfter Vismodegib Therapy for Basal Cell
Carcinoma: Not a Case-Control Study
To the Editor In the May 2016 issue of JAMA Dermatology,
Mohan et al1 report an increased risk of cutaneous squamous
cell carcinoma (CSCC) after vismodegib therapy for basal cell
carcinoma (BCC).1 They collected data froma cohort of 55 pa-
tientswithBCCtreatedwithvismodegibandcompared the risk
of CSCC with that in a cohort of 125 patients with BCC not
treated with vismodegib. The authors present the study as a
case-control study, which it is not.
Thedefinition of a case-control study canbe found in any
textbook in basic epidemiology:A case-control study is a type
of observational study in which 2 existing groups differing in
outcomeare identifiedandcomparedonthebasisof somesup-
posed causal attribute.2 The 2 groups in the study by Mohan
et al1 were selected on the basis of a difference in a possible
risk exposure (ie, vismodegib treatment) and, when com-
pared, found to differ in outcome (ie, CSCC).1 With this de-
sign, the study is a cohort study in which 2 cohorts were fol-
lowedlongitudinally tocompareoutcomes.Datawerecollected
retrospectively, but this doesnotmake it a case-control study.
The study has other andmore importantmethodological
concerns thanbeingmislabeledacase-control study.Theseare,
however, nicely discussed by the authors1 and in an accom-
panying editorial by Rübben et al.3
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To the EditorWe readwith concern the article byMohan et al.1
First, this is not a case-control study inwhichparticipants are
sampled based on the presence (case) or absence (control) of
a given disease. Instead this is a retrospective cohort study of
patients exposed or not exposed to vismodegib.
Inaddition,non–basal cell carcinoma(BCC)secondarycan-
cersweredefinedasbeingassociatedwithvismodegib therapy
if they were diagnosed at least 2 weeks after the first expo-
sure to vismodegib. Is it possible to include events occurring
so early after treatment?
Accordingto thecrudeanalysis, therateof subsequentcan-
cers was much lower in exposed (29.1%) than in nonexposed
(40.0%) patients. Is it possible that in the Cox model, owing
to adjustment, the result is completely reversed leading to a
hazard ratio of 6.37?
Clinical follow-up durations were not statistically differ-
ent, although the follow-up duration of exposed patientswas
much longer than that of nonexposed patients (median 8.5
years vs 5.5 years). This could be a possible source of bias and
should be discussed.
Thesameobservation isvalid for latencyperiod,whichwas
longer (even though not statistically significant) in exposed
than in nonexposed patients. Thismeans that in exposed pa-
tients, it took longer to develop secondary cancers, which is
the opposite of what was stated in the article. There is no in-
formation about patients lost to follow-up or thosewho died.
Similar cohorts of patients with advanced BCC have an an-
nual mortality of more than 7%.2
Finally, the Kaplan-Meier curve shown in Figure 21 is in-
appropriate because only patients who developed cutaneous
squamous cell carcinomaswere included. In a survival curve,
it is necessary to include all participants. It seems that all ex-
posed and all nonexposed patients developed a cutaneous
squamous cell carcinoma. However, the numbers of patients
at risk do not match the figure.
Taking into account all the criticisms of the report by
Mohan et al,1 we believe that there is inadequate evidence to
suggest that vismodegib treatment increases the risk of non-
BCC secondary cancers.
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In ReplyWe agree with Gjersvik and Puig et al that our study1
is a retrospective cohort study and thank thewriters for clari-
fying this. According to the textbook Epidemiology in Medi-
cine by Hennekens et al,
Considerable confusionhasarisen concerning the terms ret-
rospective and prospective as applied to epidemiologic studies.
Some investigators have used these terms synonymously with
case-control and cohort, respectively, reasoning that the for-
mer looks backward fromadisease to apossible cause,while the
latter looks forward fromanexposure toanoutcome…While this
terminology is theoretically applicable to case-control studies,
it has the greatest practical utility for differentiating two main
types of cohort studies, i.e. retrospective and prospective co-
hort studies.2(p23)
Therefore, themore useful way to label our study is retro-
spective cohort study, rather thancase-control. Theexposure is
aSmoothened inhibitor, andtheoutcome is secondcancer.The
cohortconsistedofpatientswithbasalcellcarcinoma(BCC).The
study is retrospective as it analyzed data from 1998 to 2014.
To address the question raised by Puig et al regarding
rapid appearance of squamous cell carcinoma (SCC) being
defined as 2 weeks after Hedgehog blockade, we have
observed the new onset of SCCs 2 weeks after initiation of
Hedgehog blockade in a patient who clearly did not have a
lesion prior to Smoothened initiation (unpublished data). In
addition, examples of other similar observations in the lit-
erature where SCC develops rapidly after targeted therapy
include (1) the onset of SCC after vemurafenib within 1 to 6
months after start of vemurafenib therapy3 and (2) the onset
of SCC after 3 months of ustekinumab treatment.4 This was
the reasoning behind defining second cancer after 2 weeks
in our study.
Regarding the question raised by Puig et al on the pri-
mary objective of the study, the findings of crude analysis of
all non-BCC secondary cancers were indeed 29.1% in ex-
posed and40.0% innonexposedpatients.However, this does
not account for time to exposure (vismodegib) and time to
event (second cancer). The Cox proportional hazard ratio ac-
counted for time and treatedvismodegib exposure (or nonex-
posure) as a time-dependent variable.
Puig et al raised concern about the variation in follow-up
time (despite the lack of statistical significance). To further
convince readers that the variation in follow-up time was
not significant, we conducted a subset analysis that included
patients whose BCC diagnosis was in the year 2008 or after.
The median follow-up times were 2.4 (range, 0.1-6.3) years
and 1.4 (range, 0.3-6.1) years for nonexposed (n = 56) and
exposed groups (n = 24), respectively (P = .49). Neverthe-
less, the hazard ratio was still significant, at 3.24 (95% CI,
1.28-8.22) (P = .01).
To clarify Figure 2 in our study,1 because we handled vis-
modegib exposure as a time-dependent variable, the
observed Kaplan-Meier survival curves could not be gener-
ated. Instead, the survival function was estimated, and the
predicted survival curves were generated. Thus, this may
have led to confusion with the more commonly used
Kaplan-Meier curves. We apologize that this was not made
clear in the article.
In summary, my coauthors and I believe that the results
of our study are correct, even thoughwe agree that terminol-
ogy and explanations could have been more clear. We thank
the writers for their comments and hope that our responses
have clarified the questions.
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CORRECTION
Errors inTables: In theOriginal Investigation titled “AssociationBetweenChanges
in Coronary Artery Disease Progression and Treatment With Biologic Agents for
Severe Psoriasis,”1 published online July 7, 2016, there were errors in the tables.
Table 1 should have a footnote defining “ever smoked” that reads as follows: “De-
fined as current tobacco use or smoked at least 100 cigarettes/approximately
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